About Us

About Cytoimmune Therapeutics

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently we are developing our proprietary Chimeric Antigen Receptor (CAR) engineered NK cells (CAR-NK) technology, which we licensed from the laboratories of Drs. Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center (COH).

Leadership

Christina-Coughlin

Christina Coughlin, M.D., Ph.D. has been appointed the CEO of CytoImmune Therapeutics. Dr. Coughlin joined CytoImmune from Rubius Therapeutics, Inc. where she served as the Chief Medical Officer and led the clinical development, translational medicine and regulatory efforts in the allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the development of autologous CAR-T and TCR-T cellular therapies.

Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career including Chief Medical Officer at Immunocore, heading the development of the soluble TCR platform, and Oncology Asset Team Leader at Pfizer. Dr. Coughlin received her M.D. and Ph.D. from the University of Pennsylvania and completed fellowships in Hematology and Oncology at the Children’s Hospital of Philadelphia and in the Translational Research Group under the direction of Carl June, M.D. at the University of Pennsylvania.

MichaelACaligiuriMD
Experience:
  • President, City of Hope National Medical Center
  • Deana and Steve Campbell Physician-in-Chief Distinguished Chair
  • Past President, AACR
  • Elected to National Academy of Medicine for breakthrough human NK cell and T cell discoveries

Michael A. Caligiuri, M.D., is the President of the City of Hope Natonal Medical Center and holds the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He is a world-renowned physician, scientist, builder, innovator, leader and visionary. Dr. Caligiuri is dedicated to developing the next generation of leading-edge immune therapies for cancer, rapidly delivering them to patients and ultimately curing the disease.

Prior to joining City of Hope, Dr. Caligiuri worked for 20 years as a physician, scientist and leader in the cancer program at The Ohio State University. He spent the past decade as CEO of The James Cancer Hospital and Solove Research Institute and directed The Ohio State University Comprehensive Cancer Center for 14 years, recruiting over 300 cancer physicians and scientists and building the 3rd largest cancer hospital in America.

Dr. Caligiuri has spent the last 35 years studying human natural killer (NK) cell biology during which time he made several seminal discoveries that have paved the way for CAR NK cells to advance into the clinic. He has over 400 peer-reviewed original research publications on NK cells and/or cancer. Over 1,000 patients have been treated on clinical trials designed or co-designed by Dr. Caligiuri to modulate NK cells for cancer therapy.

Dr. Caligiuri is the past president (2018) of the American Association for Cancer Research (AACR), the world’s largest cancer research organization with 40,000 members in 120 countries. He was elected as a Fellow to the AACR Academy, received a lifetime achievement award from Stanford University School of Medicine and was elected to the US National Academy of Medicine for his basic and translational work on human NK cells and cancer.

Aleksey-Krylov
Experience:
  • Multiple fundraising and exit deals
  • Emerging biotech and pubco CFO

Aleksey Krylov is a strategic CFO to life sciences companies with the background in private equity investing. Most recently, he served as a Chief Financial Officer of DIH International, Ltd., a Swiss-Chinese medical equipment manufacturer with $80m in sales and 400 employees globally.

Previously, he was an Chief Financial Officer of SELLAS Life Sciences, Inc. (NASDAQ: SLS, peak market cap ~$170m), an oncology immuno-therapeutics company. At SELLAS he led the reverse merger of private SELLAS into a publicly listed target and raised $10.7 million in financing. At both companies, he was responsible for managing financial, investor relations and administrative operations of the company.

Prior to becoming CFO, Mr. Krylov was a family office investment professional with a focus on M&A, capital raising, private equity investing and restructuring. His industries of interest included life sciences, medical technologies, healthcare IT and consumer products, among others.

Krylov began his career with SG Cowen’s equity capital markets group as an investment banking analyst in 2002. Mr. Krylov holds an M.B.A. from Columbia Business School and a B.S. in Business Administration from Babson College. He is a CFA charterholder.

William-Rosellini
Experience:
  • 5 exits, 3 public offerings (OTC:QB “NXNN”), (TSX.V “PINK”), (NYSE:”DSS”)

Rosellini is the President of CytoImmune Therapeutics. Previously, Rosellini was the CEO of Perimeter Medical, Inc. He also led Nexeon Medsystems, Inc., a medical device manufacturing company that went public in 2017. Before that he founded and led Lexington Technology Group, LLC, a database company commercializing a electronic health record database solution to an exit (“DSS” NYSE).

Before that he founded Sarif Biomedical LLC, a stereotactic cancer microsurgery with IP spun-out of Medtronic and led company to an exit with Marathon Patent Group, Inc. (“MARA” NSDQ). He subsequently served on the Marathon board of directors and chaired the Audit committee. Rosellini completed 2 acquisitions to form Telemend Medical, Inc. a clinical engineering services company and led that company to an exit in 2016. Rosellini was also CEO at Microtransponder, an implantable neurostimulation developer with solutions for stroke rehabilitation. He is a former minor league pitcher with the Diamondbacks of the Arizona League, holds a JD, MBA, MS of Accounting, MS of Computational Biology, MS of Neuroscience and MS of Regulatory Science.

Lei-Zhang
Experience:
  • Manager, Gel Elelectrophoretic and Pathway Analysis Services
  • Research Fellow, Department of Cellular and Molecular Biology at City of Hope
  • Postdoctoral scholar, Department of Pathology and Laboratory Medicine at University of Kentucky

Accomplished, bilingual, medical research professional with a solid history of success performing extensive research to provide valuable diagnoses; positioned to excel in demanding pharmaceutical and biotechnology research environment. Extensive medical, pharmacological, and administrative knowledge complemented by advanced study and practice in protein analysis, immunology and oncology. Proven resource planning and cost reduction skills to ensure adherence to standard medical research practices while meeting target objectives. Expert in nurturing an excellent relationship with everyone within the organizational premises . Providing Services with a core value of Sense of Urgency. Technical proficiency in Multiple Bioinformatics data analysis, MetaCore Enrichment Analysis, Ingenuity Pathway Analyses (IPA) , DAVID Bioinformatics Resources , STRING Database functional protein association networks Analysis, Adobe Photoshop, TotalLab Samespot, PDQuest Advanced, Spectrometer, Mascot, Proteome Discoverer, Progenesis QI, Flowjo and MS Office.

Experience:
  • Manufacturing Manager in Amgen
  • Sr. Engineer in Juncos, Pr, Puerto Rico
  • Manufacturing Associate, Kelly Scientific Resources

Yishara joined CytoImmune on May 2021 as Manufacturing & Operations Lead. She brings 10+ years of experience in the biopharma from Amgen Puerto Rico. She has held roles of increasing responsibilities through the manufacturing and engineering organizations from manufacturing associate, Sr. manufacturing associate, process owner, manufacturing specialist, Sr. engineer and manufacturing manager. She brings the experience of cGMP, GDP, GLP, 12 principles of manufacturing NPI, Process improvements (yield and cost reductions), CAPAs, process monitoring & design, risk management and FDA audits support. Yishara holds a bachelor’s degree in chemistry from UPR Rio Piedras and a bachelor’s degree in chemical engineering from the Polytechnic University.

Experience:
  • Associate Director & Principal Scientist, R&D/CMC INVECTYS, USA
  • Senior Scientist, R&D / Translational Medicine, Bellicum Pharmaceuticals, INC.

Tania Rodriguez is the Director of Research in CytoImmune Therapeutics. Formulates the strategy and design of preclinical studies for IND filing and manages collaborations with CROs. Prepare action plans and budgets for preclinical and process development (PD) activities. Supports technology transfer activities for CAR-NK manufacturing and improves the process to decrease costs while maintaining quality. Manages PD scientists at the junior and senior level. Collaborate in cross-functional meetings to achieve corporate goals. Reports to the Chief Operating Officer (COO).

Immunologist with 5+ years of pharmaceutical industry experience in cancer immunotherapy with expertise in chimeric antigen receptor (CAR)-based cell therapy development, generation of regulatory documents for IND applications, and development of biomarker strategies to support clinical protocols.

Dr. Rodriguez received her Ph.D. in Immunology from the University of Texas Graduate School of Biomedical Sciences/MD Anderson Cancer Center. She conducted Post-Doctoral research work on CAR-T cells at Baylor College of Medicine in the Cell and Gene Therapy Department under the direction of Stephen Gottschalk M.D. and Malcom K. Brenner, M.D. Ph.D.

Experience:
  • Director of Validation Services, TriPharm Services, Morrisville, NC
  • Sr Manager Pharm Eng, Gilead Sciences, Foster City, CA
  • EASi – QA Consultant. Vistakon, Jacksonville, Florida Area

Jose Edgardo joined CytoImmune from TriPharm in North Carolina where he served as head of Validations. During his time at TriPharm, Jose Edgardo led the commissioning and qualification of their new state of the art 32,000 sqft aseptic processing facility.

Prior to TriPharm, Jose Edgardo led the Pharmaceutical Engineering team at Gilead in California. Earlier in his career, he worked at J&J, Pfizer and Wyeth Pharmaceuticals in the Quality, Manufacturing and Technical Services organizations. Jose Edgardo received a Master of Science in Chemical Engineering from the University of Puerto Rico, Mayaguez campus. He enjoys the outdoors and traveling with his wife Mariluz and his African grey parrot, Beto.

Experience:
  • Manager in QC Biochemistry Department, Amgen Manufacturing Limited, Puerto Rico
  • Manager in QC Microbiology Department, Amgen Manufacturing Limited, Puerto Rico
  • Specialist, QC Technical Resources Department, Amgen Manufacturing Limited, Puerto Rico

Doel Gomez is the Quality Control Associate Director in CytoImmune Therapeutics. Manager with 18 years of experience in Biotechnology Parenteral Drug Substance and Drug Product Manufacturing Quality Control (QC) Laboratories.

Doel has Technical expertise in Quality Control Microbiology and Biochemistry Laboratory Processes (GMP/GDP’s Environment). Experience managing teams that delivered analytical results of Biological Drugs (Proteins and Monoclonal Antibodies) and Small Molecules (API’s). Managed teams supporting analytical methods validation, method transfers, laboratory investigations (OOS / UR’s), quality systems. Experience supporting QC microbiological analysis of raw materials, water samples, microbial environmental monitoring, intermediate product samples, drug substance bioprocessing samples, finished drug products and Stability programs.

Experience:
  • Senior Supply Chain Manager in Stryker
  • Manufacturing Manager in Abbvie LTD
  • Logistics & Contract Administrator Manager in Abbott Laboratories

Jose Juan Acevedo is the Head of Supply Chain in CytoImmune Therapeutics. He has Supply Chain Management and Operations professional with 20 years of experience. Driven communicator and leader, focused on coaching and motivate teams in challenging organizational environments.

Areas of expertise: Procurement, Manufacturing Operations, Logistics, Financial Management, Production Planning, GMP Compliance, Project Management & Lean Principles.

Board of Directors

Richard

Rich Santulli, was the founder and chairman of Milestone Aviation Group, a helicopter and business jet leasing company. He is best known for pioneering the concept of fractional jet ownership with NetJets, a company he developed in 1986. Santulli was once considered a possible successor to Warren Buffett at Berkshire Hathaway.

Christina-Coughlin

Christina Coughlin, M.D., Ph.D. has been appointed the CEO of CytoImmune Therapeutics. Dr. Coughlin joined CytoImmune from Rubius Therapeutics, Inc. where she served as the Chief Medical Officer and led the clinical development, translational medicine and regulatory efforts in the allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the development of autologous CAR-T and TCR-T cellular therapies.

Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career including Chief Medical Officer at Immunocore, heading the development of the soluble TCR platform, and Oncology Asset Team Leader at Pfizer. Dr. Coughlin received her M.D. and Ph.D. from the University of Pennsylvania and completed fellowships in Hematology and Oncology at the Children’s Hospital of Philadelphia and in the Translational Research Group under the direction of Carl June, M.D. at the University of Pennsylvania.

Kinam Hong

Kinam joined Sofinnova Partners in January 2017. Kinam co-managed the Exane Equinox fund, a global healthcare fund with a focus on later-stage, public biotechnology companies. Kinam invested in global life sciences companies developing innovative medicines with the potential to address areas of large unmet medical need.

Kinam had previously spent 10 years as an investor and analyst covering the biotechnology sector, including at Citigroup investment research where he focused on small- and mid-cap biotechnology companies.

Prior to his investment career, Kinam worked in new product development at Sanofi, a multi-national pharmaceutical company, where he managed a HIV vaccine candidate in Phase 3 development. Kinam also held roles in business development and strategic marketing, where he worked on various infectious diseases and oncology licensing deals and on Sanofi’s strategy in China, respectively.
Kinam is a medical doctor and holds degrees in molecular biology/biochemistry and medicine from the University of Florida. He also holds a CFA (Chartered Financial Analyst) and MBA from INSEAD (France).

Doug-Williams

Douglas E. Williams, Ph.D., is Codiak’s President and CEO. He previously served as Biogen’s Executive Vice President, Research and Development from January 2011 to July 2015.

Dr. Williams joined Biogen from ZymoGenetics, where he was CEO and member of the Board of Directors. ZymoGenetics was acquired by Bristol Myers Squibb during his time as CEO for $985 million. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics Inc., and Senior Vice President and Washington Site Leader at Amgen Inc.

Dr. Williams also served in a series of scientific and senior leadership positions over a decade at Immunex Corp., including Executive Vice President and Chief Technology Officer, Senior Vice President of Discovery Research and Vice President of Research and Development.

Prior to joining Immunex, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, New York. Dr. Williams has served on numerous boards of directors for companies in the biotechnology industry and is currently a member of the Board of Directors of Ovid Therapeutics, Chairman of the Board of AC Immune, and is a Director for private companies Cygnal Therapeutics and Xenikos.

Scientific Advisory Board

Jianhua-Yu

Jianhua Yu, Ph.D., has joined City of Hope as a professor in the Department of Hematology & Hematopoietic Cell Transplantation. He is a member of the Hematologic Malignancies and Stem Cell Transplantation Institute and founding director of the NK Cell Biology Research Program within the Center for T Cell Immunotherapy of the institute.

Yu’s research interests include NK cell biology, chimeric antigen receptor (CAR) NK cells, CAR T cells, oncolytic virus, bispecific antibodies, natural product-based therapeutics and hematopoietic stem cell transplantation. His lab focuses on both basic and translational research relevant to developing innovative cellular immunotherapy and oncolytic virotherapy for the treatment of cancers such as multiple myeloma, acute myeloid leukemia and glioblastoma.

Prior to joining City of Hope, Yu was a tenured professor in the Division of Hematology of the College of Medicine and the Comprehensive Cancer Center at The Ohio State University. Yu received his Ph.D. degree from Purdue University in 2003 and then moved to The Ohio State University for his postdoctoral training, where he subsequently accepted a junior faculty position and advanced through the tenure track.

Yu has authored or co-authored over 160 publications, many of the which are in high-impact journals, in the field of natural killer cell biology, cancer immunotherapy, oncolytic virotherapy, hematopoietic stem cell transplantation, etc. Work from Yu and his colleagues has also resulted in about 10 patents (awarded or pending).

In 2015, Yu received The Jack Latham Memorial Award for Innovative Research from the American Association of Blood Banks and the Janet D. Rowley Medical Award from Gabrielle’s Angel Foundation and FAME Faculty of the Year Award for researchers from College of Medicine at The Ohio State University. Yu is a scholar at several national research foundations including the National Blood Foundation Scholar and the Leukemia & Lymphoma Society.